# Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies

> **NCT03682029** · NA · UNKNOWN · sponsor: **Rigshospitalet, Denmark** · enrollment: 109 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia-1
- Cytopenia

## Interventions

- **DIETARY_SUPPLEMENT:** Vitamin C (ascorbic acid)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03682029
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-21
- **Primary completion:** 2023-09-27
- **Final completion:** 2025-09-27
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03682029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03682029, "Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03682029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*